Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Limping Toward Weekend

10/08/2021 | 01:53pm EST


ę MT Newswires 2021
All news about ALLOGENE THERAPEUTICS, INC.
11/15ALLOGENE THERAPEUTICS : Corporate Presentation - November 2021
PU
11/12Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Confere..
GL
11/12Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Confere..
GL
11/05Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL Al..
AQ
11/04Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update ..
PU
11/04ALLOGENE THERAPEUTICS : Q3 Earnings Snapshot
AQ
11/04ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/04Allogene Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
11/04Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Updateá..
AQ
11/04Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL Al..
AQ
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 38,4 M - -
Net income 2021 -265 M - -
Net cash 2021 492 M - -
P/E ratio 2021 -9,15x
Yield 2021 -
Capitalization 2 562 M 2 562 M -
EV / Sales 2021 53,9x
EV / Sales 2022 852x
Nbr of Employees 301
Free-Float 52,2%
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 17,98 $
Average target price 35,19 $
Spread / Average Target 95,7%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-28.76%2 562
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678